Hampel, H;
Toschi, N;
Baldacci, F;
Zetterberg, H;
Blennow, K;
Kilimann, I;
Teipel, SJ;
... Lista, S; + view all
(2018)
Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A beta(1-42), total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40.
Alzheimer's & Dementia
, 14
(4)
pp. 492-501.
10.1016/j.jalz.2017.11.015.
Preview |
Text
Zetterberg_HampelAlzheimersDementia.pdf - Accepted Version Download (726kB) | Preview |
Abstract
INTRODUCTION: The diagnostic and classificatory performances of all combinations of three core (amyloid β peptide [i.e., Aβ1–42], total tau [t-tau], and phosphorylated tau) and three novel (neurofilament light chain protein, neurogranin, and YKL-40) cerebrospinal fluid biomarkers of neurodegeneration were compared among individuals with mild cognitive impairment (n = 41), Alzheimer's disease dementia (ADD; n = 35), frontotemporal dementia (FTD; n = 9), and cognitively healthy controls (HC; n = 21), using 10-fold cross-validation. METHODS: The combinations ranking in the top 10 according to diagnostic accuracy in differentiating between distinct diagnostic categories were identified. RESULTS: The single biomarkers or biomarker combinations generating the best area under the receiver operating characteristics (AUROCs) were the following: the combination [amyloid β peptide + phosphorylated tau + neurofilament light chain] for distinguishing between ADD patients and HC (AUROC = 0.86), t-tau for distinguishing between ADD and FTD patients (AUROC = 0.82), and t-tau for distinguishing between FTD patients and HC (AUROC = 0.78). CONCLUSIONS: Novel and established cerebrospinal fluid markers perform with at least fair accuracy in the discrimination between ADD and FTD. The classification of mild cognitive impairment individuals was poor.
| Type: | Article |
|---|---|
| Title: | Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A beta(1-42), total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40 |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.jalz.2017.11.015 |
| Publisher version: | http://dx.doi.org/10.1016/j.jalz.2017.11.015 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences & Neurology, Alzheimer's disease, Alzheimer's disease dementia, Diagnostic biomarkers, Biomarker combination, Cerebrospinal fluid, Neurofilament light chain, Neurogranin, YKL-40, Pathophysiological pathways, Neurodegeneration, Clinical diagnosis, Cognitive aging, Mild cognitive impairment, Frontotemporal dementia, Precision medicine, NEUROFILAMENT LIGHT, NATIONAL INSTITUTE, NEURODEGENERATIVE DISEASES, ASSOCIATION WORKGROUPS, DEGENERATION, PROTEIN, STANDARDIZATION, GUIDELINES, MARKERS, CSF |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10057515 |
Archive Staff Only
 |
View Item |
